169 related articles for article (PubMed ID: 36759009)
1. Lipid management in systemic lupus erythematosus according to risk classifiers suggested by the European Society of Cardiology and disease-related risk factors reported by the EULAR recommendations.
Drosos GC; Konstantonis G; Sfikakis PP; Tektonidou MG
RMD Open; 2023 Feb; 9(1):. PubMed ID: 36759009
[TBL] [Abstract][Full Text] [Related]
2. Application of EULAR and European Society of Cardiology recommendations with regard to blood pressure and lipid management in antiphospholipid syndrome.
Drosos GC; Konstantonis G; Sfikakis PP; Tektonidou MG
RMD Open; 2023 Aug; 9(3):. PubMed ID: 37558493
[TBL] [Abstract][Full Text] [Related]
3. The impact of traditional cardiovascular risk factor control on 7-year follow-up atherosclerosis progression in systemic lupus erythematosus.
Papazoglou N; Kravvariti E; Konstantonis G; Sfikakis PP; Tektonidou MG
Rheumatology (Oxford); 2024 Jan; 63(1):50-57. PubMed ID: 37086440
[TBL] [Abstract][Full Text] [Related]
4. Generic and disease-adapted cardiovascular risk scores as predictors of atherosclerosis progression in SLE.
Panopoulos S; Drosos GC; Konstantonis G; Sfikakis PP; Tektonidou MG
Lupus Sci Med; 2023 Mar; 10(1):. PubMed ID: 36868585
[TBL] [Abstract][Full Text] [Related]
5. Atherosclerotic plaques occur in absence of intima-media thickening in both systemic sclerosis and systemic lupus erythematosus: a duplexsonography study of carotid and femoral arteries and follow-up for cardiovascular events.
Frerix M; Stegbauer J; Kreuter A; Weiner SM
Arthritis Res Ther; 2014 Feb; 16(1):R54. PubMed ID: 24548804
[TBL] [Abstract][Full Text] [Related]
6. Eligibility for lipid-lowering therapy when applying systemic coronary risk estimation 2 (SCORE2) according to guidelines on apparently healthy middle-aged individuals.
Yari A; Ueda P; Lundman P; Alfredsson J; Ravn-Fischer A; Söderberg S; Yndigegn T; Hagström E; Jernberg T
Eur J Prev Cardiol; 2024 Jun; ():. PubMed ID: 38842486
[TBL] [Abstract][Full Text] [Related]
7. Exploring the risk factors for ischemic cerebrovascular disease in systemic lupus erythematosus: A single-center case-control study.
Su L; Qi Z; Guan S; Wei L; Zhao Y
Front Immunol; 2022; 13():978910. PubMed ID: 36238309
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular risk assessment in patients with antiphospholipid syndrome: a cross-sectional performance analysis of nine clinical risk prediction tools.
Drosos GC; Konstantonis G; Sfikakis PP; Tektonidou MG
RMD Open; 2023 Nov; 9(4):. PubMed ID: 38016710
[TBL] [Abstract][Full Text] [Related]
9. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome.
Drosos GC; Vedder D; Houben E; Boekel L; Atzeni F; Badreh S; Boumpas DT; Brodin N; Bruce IN; González-Gay MÁ; Jacobsen S; Kerekes G; Marchiori F; Mukhtyar C; Ramos-Casals M; Sattar N; Schreiber K; Sciascia S; Svenungsson E; Szekanecz Z; Tausche AK; Tyndall A; van Halm V; Voskuyl A; Macfarlane GJ; Ward MM; Nurmohamed MT; Tektonidou MG
Ann Rheum Dis; 2022 Jun; 81(6):768-779. PubMed ID: 35110331
[TBL] [Abstract][Full Text] [Related]
10. Excess atherosclerosis in systemic lupus erythematosus,-A matter of renal involvement: Case control study of 281 SLE patients and 281 individually matched population controls.
Gustafsson JT; Herlitz Lindberg M; Gunnarsson I; Pettersson S; Elvin K; Öhrvik J; Larsson A; Jensen-Urstad K; Svenungsson E
PLoS One; 2017; 12(4):e0174572. PubMed ID: 28414714
[TBL] [Abstract][Full Text] [Related]
11. [Risk factors of thickened intima-media and atherosclerotic plaque development in carotid arteries in patients with systemic lupus erythematosus].
Fischer K
Ann Acad Med Stetin; 2008; 54(2):22-32. PubMed ID: 19374227
[TBL] [Abstract][Full Text] [Related]
12. Underperformance of clinical risk scores in identifying vascular ultrasound-based high cardiovascular risk in systemic lupus erythematosus.
Drosos GC; Konstantonis G; Sfikakis PP; Tektonidou MG
Eur J Prev Cardiol; 2021 Apr; 28(3):346-352. PubMed ID: 33891687
[TBL] [Abstract][Full Text] [Related]
13. Antiphospholipid antibodies and non-thrombotic manifestations of systemic lupus erythematosus.
İlgen U; Yayla ME; Ateş A; Okatan İE; Yurteri EU; Torgutalp M; Keleşoğlu ABD; Turgay TM; Kınıklı G
Lupus; 2018 Apr; 27(4):665-669. PubMed ID: 29050535
[TBL] [Abstract][Full Text] [Related]
14. Body mass index and glucocorticoid dose contribute to subclinical atherosclerosis in Korean patients with systemic lupus erythematosus: A prospective 4 year follow-up study.
Jung JY; Kim HA; Lee HY; Suh CH
Int J Rheum Dis; 2019 Aug; 22(8):1410-1418. PubMed ID: 31050219
[TBL] [Abstract][Full Text] [Related]
15. Atherosclerosis in premenopausal women with antiphospholipid syndrome and systemic lupus erythematosus: a controlled study.
Vlachoyiannopoulos PG; Kanellopoulos PG; Ioannidis JP; Tektonidou MG; Mastorakou I; Moutsopoulos HM
Rheumatology (Oxford); 2003 May; 42(5):645-51. PubMed ID: 12709540
[TBL] [Abstract][Full Text] [Related]
16. Soluble CD163 is a biomarker for accelerated atherosclerosis in systemic lupus erythematosus patients at apparent low risk for cardiovascular disease.
David C; Divard G; Abbas R; Escoubet B; Chezel J; Chauveheid MP; Rouzaud D; Boutten A; Papo T; Dehoux M; Sacre K
Scand J Rheumatol; 2020 Jan; 49(1):33-37. PubMed ID: 31161842
[No Abstract] [Full Text] [Related]
17. Carotid and femoral atherosclerosis in antiphospholipid syndrome: Equivalent risk with diabetes mellitus in a case-control study.
Kravvariti E; Konstantonis G; Tentolouris N; Sfikakis PP; Tektonidou MG
Semin Arthritis Rheum; 2018 Jun; 47(6):883-889. PubMed ID: 29150207
[TBL] [Abstract][Full Text] [Related]
18. Progression of subclinical atherosclerosis in systemic lupus erythematosus versus rheumatoid arthritis: the impact of low disease activity.
Kravvariti E; Konstantonis G; Sfikakis PP; Tektonidou MG
Rheumatology (Oxford); 2018 Dec; 57(12):2158-2166. PubMed ID: 30102390
[TBL] [Abstract][Full Text] [Related]
19. The chronic damage in systemic lupus erythematosus is driven by flares, glucocorticoids and antiphospholipid antibodies: results from a monocentric cohort.
Conti F; Ceccarelli F; Perricone C; Leccese I; Massaro L; Pacucci VA; Truglia S; Miranda F; Spinelli FR; Alessandri C; Valesini G
Lupus; 2016 Jun; 25(7):719-26. PubMed ID: 26821965
[TBL] [Abstract][Full Text] [Related]
20. [Significance of antiphospholipid syndrome and antiphospholipid antibodies in patients with systemic lupus erythematosus in estimation of risk of subclinical atherosclerosis development].
Fischer K; Brzosko M; Walecka A; Ostanek L; Sawicki M
Pol Arch Med Wewn; 2007; 117 Suppl():13-7. PubMed ID: 18778013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
